This Week In Huntington's Disease Research keeps you up-to-date on HDSA research activities, recently published work about Huntington’s disease, historical moments in HD research and more.

January, 2022

Update from Novartis on Planned Trial of Branaplam for Huntington’s Disease

Posted on January 27, 2022

Novartis is developing an experimental HD therapy called branaplam which has the potential to lower huntingtin when taken by mouth. Branaplam…

Read More

Roche to continue development of tominersen: Community Presentation TODAY

Posted on January 20, 2022

In a community letter released January 18th, Roche announced plans to continue developing the huntingtin-lowering drug tominersen. After analyzing data collected in the Phase III GENERATION HD-1 trial that halted dosing in…

Read More

Research Webinar: Roche Joins HDSA to Discuss Latest Data from GENERATION HD-1

Posted on January 13, 2022

One week from today, HDSA will be joined by members of the Roche team at 3:00 PM EST on January 20th for…

Read More

Upcoming Webinar: New Key Findings from the GENERATION HD-1 Study

Posted on January 6, 2022

Join HDSA at 3:00 PM EST on January 20th for an update from Roche on new findings from the data collected in the GENERATION HD-1 study. This…

Read More